Share |

Content about Vaccines

August 14, 2015

Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).

The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.

July 31, 2015

The Gaithersburg, Md.-based biotech that came up with a faster and innovative way to produce vaccines has announced positive data from a Phase 2 trial focused on developing an Influenza vaccine.

November 2, 2011

The biotech company narrows loss but revenues plummet

Nabi Biopharmaceuticals (Nasdaq:NABI) is recovering from its failed Phase III nicotine addiction drug trial back in July. The biotechnology company based in Rockville reported improved earnings for the third quarter ended September 26, 2011. It narrowed its net loss to $2.9 million or $-0.07 cents per share from $5.1 million or $-0.12 cents per share in third quarter of 2010 and $4.6 million in the second quarter ended June 26, 2011.

July 20, 2011

The Rockville based biotechnology company said that  Nicotine Conjugate Immunotherapeutic (NicVAX) did not meet the primary endpoints in the first trial in its Phase III study.

Typically the final stage before a drug is presented for FDA approval and gets the marketing and sales go ahead; the Phase III clinical trials for Nabi Biopharmaceuticals' NicVAX drug may be its' last stop for good.

The Rockville based biotechnology company said that  Nicotine Conjugate Immunotherapeutic (NicVAX) did not meet the primary endpoints in the first trial in its Phase III study.

July 13, 2011

Annapolis based biotechnology company PharmAthene, Inc has reached a pivotal milestone in its development of an Anthrax prevention drug.

The biodefense biotech said that its SparVax™ rPA Anthrax Vaccineachieved a 36 month final product stability.